drugset / Trial / NCT05021406
Extension Study of Carvedilol RCT Study
Non-randomizedParallel-groupOpen-labelPrevention
Summary
Patients who have completed 2-years treatment in RCT Study of carvedilol will receive another 2-years extension therapy, aiming to investigate the long-term efficacy of carvedilol for the prevention of esophageal varices in treated HBV cirrhotic patients.
Timeline
- Start
- 2021-01-08
- Primary completion
- 2024-10-30
- Completion
- 2024-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carvedilol | Other / unclassified | 12.5 mg | — |